Amid recent trading sessions, shares of Viking Therapeutics Inc (Symbol: VKTX) have broken above the average analyst 12-month target price of $36.00, transacting at $36.20/share. When a stock achieves the target set by an analyst, the ensuing logical reactions are pivotal; analysts might revise their target price upward if fundamental business developments drive stock prices higher.
There exist 8 distinct analyst targets contributing to the average for Viking Therapeutics Inc within the Zacks coverage universe, signifying a diverse array of opinions within the market. However, the objective of scrutinizing the average VKTX price target is to leverage the collective insights of numerous individuals, rather than relying solely on the opinion of one expert. The breaking of the $36.00/share average target price presents a substantial signal for investors in VKTX to dedicate fresh time to a comprehensive assessment of the company’s trajectory.
| Recent VKTX Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Month Ago | 3 Month Ago |
| Strong buy ratings: | 8 | 8 | 8 | 8 |
| Buy ratings: | 1 | 1 | 1 | 1 |
| Hold ratings: | 0 | 0 | 0 | 0 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.11 | 1.11 | 1.11 | 1.11 |
The average rating provided indicates opinions ranging from Strong Buy to Strong Sell, with 1 being Strong Buy and 5 denoting Strong Sell. This analysis incorporated data from Zacks Investment Research via Quandl.com.
The Top 25 Broker Analyst Picks of the S&P 500 »
Also see:
ETFs Holding PBH
Funds Holding FDIV
AMLX Average Annual Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
